Polgreen et al. followed up their initial finding of elevated TNF-α levels in MPS I patients with chronic pain and limited physical function [196] with a small pilot study, where MPS patients received TNF-α inhibitor adalimumab [197]. This evidence concerns the gene TNF and mucopolysaccharidosis.